Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2012 Financial Results
Date:3/11/2013

NEW YORK, March 11, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease (the "Company"), today announced its results for the fourth quarter and year ended December 31, 2012.

At December 31, 2012, the Company had cash, cash equivalents, interest receivable, and investment securities of $14.7 million, as compared to $39.5 million at December 31, 2011.  Subsequent to December 31, 2012, the Company completed an underwritten public offering of common stock, which provided proceeds to the Company of approximately $74.8 million, net of underwriting discounts and offering expenses of approximately $5.6 million.  Also subsequent to December 31, 2012, the Company received a $7.0 million milestone payment from its Japanese partner for Zerenex (ferric citrate), Japan Tobacco Inc. ("JT") and Torii Pharmaceutical Co., Ltd. ("Torii"), related to JT's January 2013 filing of a New Drug Application ("NDA") with the Japanese Ministry of Health, Labour and Welfare for marketing approval of ferric citrate in Japan for the treatment of hyperphosphatemia in patients with chronic kidney disease.

The net loss for the fourth quarter ended December 31, 2012 was $6.6 million, or $0.09 per share, compared to a net loss of $8.4 million, or $0.12 per share, for the comparable quarter in 2011, representing a decrease in net loss of $1.8 million.  The change in net loss in the fourth quarter of 2012, as compared to the fourth quarter of 2011, was primarily attributable to a $3.1 million decrease in research and development expenses due to the cessation of the development of KRX-0401 (perifosine) in May 2012, partially offset by a $1.3 million increase
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Fourth Quarter and Year-End 2012 Financial Results
2. Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare Conference
3. Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
4. Keryx Biopharmaceuticals Announces $55 Million Proposed Public Offering of Common Stock
5. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
6. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
8. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
9. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
10. Par Pharmaceutical Announces Quarterly Conference Call
11. HeartWare International, Inc. Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ... biology, human genetics, genomic technology, and drug discovery ...
(Date:1/15/2014)... FORT WORTH, Texas , Jan. 15, 2014 /PRNewswire/ ... "Lifetime in Dermatology Achievement Award" from the Journal ... Orlando Dermatology Aesthetic & Clinical Conference (ODAC). The event ... in Florida . ... comprehensive report on the practice of dermatology for clinical ...
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of ... able to protect their most important business ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Device Industry, it steadfastly remains one of ... involving IP infringement. This litigious nature can ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
... Inc. magazine has ranked Universal SmartComp #503 ... fourth annual Inc. 5000, an exclusive ranking of the ... comprehensive look at the most important segment of the ... 7-Eleven, Brooklyn Brewery, and Radio Flyer, maker of the ...
... SILVER SPRING, Md., Sept. 24 The U.S. ... an estrogen/progestin combined oral contraceptive that also contains ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) (Logo: ... a metabolite of folic acid, a water-soluble B-vitamin ...
Cached Medicine Technology:Universal SmartComp Ranks No. 503 Overall and No. 35 in the Health Sector on the 2010 Inc. 5000 with Three-Year Sales Growth of 600% 2Universal SmartComp Ranks No. 503 Overall and No. 35 in the Health Sector on the 2010 Inc. 5000 with Three-Year Sales Growth of 600% 3FDA Approves Combination Contraceptive Containing a Folate 2
(Date:4/15/2014)... States have nearly doubled since 1988, suggests new research ... with obesity apparently to blame for the surge. The ... has not hit all groups equally, with alarming increases ... According to new research reported in the April 15, ... , diabetes increased from 6 percent to 10 percent ...
(Date:4/15/2014)... have solved a decades-old medical mystery and in the ... invasive fungal infections, which kill about 1.5 million people a ... action of amphotericin, an antifungal drug that has been in ... is nearly as toxic to human cells as it is ... of the new findings appears in Nature Chemical Biology ...
(Date:4/15/2014)... School of Medicine have identified a mechanism that explains ... disease and why the virus is able to persist ... hard-to-kill pathogen, which infects an estimated 200 million people ... mitochondria dismantling the cell,s innate ability to fight ... , The study, published in today,s issue of the ...
(Date:4/14/2014)... children orphaned by HIV/AIDS in South Africa may provide ... emotional behavior issues in other areas of the world, ... research that could lead to successful interventions. , ... the United Nations mentions that due to the HIV/AIDS ... Sub-Saharan African, children are at an increased risk for ...
(Date:4/14/2014)... Va., USA The International and American Associations ... titled "Rare Bone Diseases and Their Dental, Oral, ... Sunday O. Akintoye, Andrea B. Burke, Alison M. ... Gafni, Janice S. Lee, Mary Scott Ramnitz, Martha ... in the OnlineFirst portion of the IADR/AADR ...
Breaking Medicine News(10 mins):Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Breaking bad mitochondria 2Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Rare bone diseases and their dental, oral and craniofacial manifestations 2
... Practice Arm of the School,s Department of Forensic ... Jan. 30 The Chicago School of ... its psychology services to the legal sector and ... thanks to its new Forensic Center, which was ...
... Kroger Co. (NYSE: KR ),said today it is ... stores,because the product was associated with peanut butter supplied by ... Stores under the following names in ... Kroger, Ralphs, Fred Meyer, Food 4 Less, Fry,s,King Soopers, ...
... grid of small arteries at the surface of the brain ... supply to tissue starved of nutrients and oxygen following a ... is optimistic news," said David Kleinfeld, a physics professor at ... flow in animal models of stroke. , Damage from stroke ...
... ) AMDL, Inc. (NYSE Alternext US: ADL), a vertically ... the US, announced today the second and final closing ... notes and warrants. The exclusive placement agent for ... on December 8, 2008, AMDL sold $1,077,500 of 12% ...
... school shootings, other tragedies , , FRIDAY, Jan. 30 (HealthDay ... people into hotheads. , A University of Kentucky study ... likely to view other people,s actions as hostile and ... , The researchers said their findings may help explain ...
... up bad lipoproteins, researchers say , , FRIDAY, Jan. ... (HDL) -- the "good" cholesterol -- may hold ... the deadly cardiovascular disease it can cause. , ... is close in size to natural HDL with ...
Cached Medicine News:Health News:New Chicago School of Professional Psychology Forensic Center Opens Doors to the Community 2Health News:New Chicago School of Professional Psychology Forensic Center Opens Doors to the Community 3Health News:Kroger Recalls Nut Topping Due to Possible Health Risk 2Health News:Mesh-like network of arteries adjusts to restore blood flow to stroke-injured brain 2Health News:AMDL, Inc. Announces Final Closing of Private Placement of Senior Notes 2Health News:AMDL, Inc. Announces Final Closing of Private Placement of Senior Notes 3Health News:Those Who Feel Rejected Direct Hostility Toward Others 2Health News:Synthetic HDL Could Fight Heart Disease 2
... Detection Reagents provide molecular labs a more ... By using our MGB technology, combined with ... now able to provide molecular labs more ... of specific organisms or genetic mutations associated ...
... MGB Alert Detection Reagents provide molecular labs ... based assays. By using our MGB technology, ... Nanogen is now able to provide molecular ... acid sequences of specific organisms or genetic ...
... and most advanced fecal occult blood test ... immunochemical FOBT (iFOBT) with high specificity and ... detect bleeding associated with more cancers and ... its superior specificity for lower GI bleeding, ...
... Capture vital signs faster, easier, ... Signs LXi, the latest innovation in ... With Spot LXi, you get more ... the flexibility to customize it to ...
Medicine Products: